| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_556e190d2e3de8afc43272aeef7b6ae7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2008-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_447059916f07780b8c4351333e35b494 |
| publicationDate |
2009-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009074761-A1 |
| titleOfInvention |
Therapeutic beta-glucan combinations |
| abstract |
A therapeutic composition for treating a proliferative disorder includes a VEGF antagonist and β-glucan. VEGF is overexpressed in some tumor types. The efficacy of treatment with VEGF antagonists capable of activating complement in combination with β-glucan is significantly increased. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016073763-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017120604-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10272101-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10111901-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011077093-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10111900-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107106593-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015159134-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106687122-A |
| priorityDate |
2007-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |